Table 1.
Patient characteristics
| Patient | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| Age range (years) | 40s | 40s | 30s | 60s | 50s | 20s | 20s | 70s | 50s | 60s |
| Gender | F | M | M | F | M | F | F | M | M | M |
| Ethnicity | White | Hispanic | Asian | Black | White | Hispanic | Black and Hispanic | White | South Asian | White |
| Height (cm) | 163 | 152 | 182 | 163 | 173 | 157 | 175 | 188 | 173 | 191 |
| Weight (kg) | 59 | 100 | 82 | 100 | 79 | 59 | 127 | 96 | 77 | 136 |
| BMI | 22 | 43 | 25 | 38 | 27 | 24 | 41 | 27 | 26 | 37 |
| Smoking History | N | Y | N | Ex | Ex | N | N | N | Ex | Ex |
| Comorbidities | Epilepsy | N | N | HTN | HTN and hyperlipidaemia | N | N | Chronic pancreatitis and MI | Hyperlipidaemia | N |
| Regular medication | Kepra | Nifedipine, telmisartan and HCT. | Lisinopril and atorvastatin. | Metoprolol, ASA and rosuvastatin. | ASA and rosuvastatin. | |||||
| Tylenol | Once | 1–2×/day 1 mg | For 5 days | |||||||
| Test method | Nasal swab PCR | Nasal swab PCR |
Nasal swab PCR |
AB test* | Nasal swab PCR |
Nasal swab PCR |
Nasal swab PCR |
Clinical diagnosis | Nasal swab PCR |
AB test* |
| Test date | 04/03 | 03/27 | 03/30 | 05/01 | 04/10 | 04/20 | 04/20 | 04/30 | 04/16 | 05/04 |
| Start symptoms | 03/24 | 03/25 | 03/21 | 04/03 | 04/10 | 04/12 | 04/15 | 03/10 | 04/14 | 03/23 |
| Start Fam. | 03/28 | 04/02 | 03/30 | 04/13 | 04/16 | 04/21 | 04/21 | 04/05 | 04/16 | 03/30 |
| Stop Fam. | 04/07 | 04/12 | 04/05 | 04/24 | 04/23 | 05/08 | 05/02 | 04/09 | 05/06 | 04/03 |
| Fam. dose | 80 mg three times a day | 80 mg three times a day | 80 mg three times a day | 50 mg three times a day | 80 mg three times a day | 80 mg three times a day | 80 mg three times a day | 60 mg two times per day | 60 mg two times per day | 20 mg three times a day |
| Symptoms† | ||||||||||
| Body ache | Y | Y | Y | Y | Y | |||||
| Chest tightness | Y | Y | Y | |||||||
| Others | Sweating. | Chills and hives. | Body spasms. | Sore throat. | Congested nose and GI symptoms. | Sinusitis/congested nose. | Slow motion performance. | GI symptoms and dehydration. | Influenza symptoms. | |
| AEs | Racing heartbeat and dizziness. | Dizziness, dry skin and insomnia. | (GI symptoms and forgetfulness) |
In order to comply with journal guidelines for anonymisation ages are provided as age ranges.
*Pt 4: test by Mount Sinai Health Systems, USA, titre: 2880; pt 10: test by Mount Sinai Health Systems, USA, titre: 2880.
†In addition to those symptoms scored in the questionnaire; dates displayed as month/day.
AB, antibody; AEs, adverse events, in parenthesis if only possibly related to famotidine; BMI, body mass index; F, female; Fam., famotidine; HCT, hydrochlorothiazide; HTN, hypertension; M, male; N, no; Y, yes.